Agree completely. I think it was a great value buy as well.
I'm glad the biotech industry took a nosedive today because I was able to make two more purchases on NVAX and another purchase in ARRY. Not sure what caused the dip on most biotechs today except maybe that they have been hot lately and maybe they're giving some gains, but because I'm planning on holding a handful for quite some time, I'll take advantage of the dips and add more when I can.
Today NVAX went below the price that they just offered the secondary at ($2.15), and I don't think it'll stay down below it too long. If it goes into the $2.75 range for some reason, I'll happily add again.
News 
Market Data 
Discover 
AI
